

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Pharmaron Beijing Co., Ltd.*

康龍化成(北京)新藥技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3759)

(I) POLL RESULTS OF THE SECOND EXTRAORDINARY GENERAL MEETING OF 2022;

(II) CESSATION OF OFFICE OF INDEPENDENT NON-EXECUTIVE DIRECTORS;

(III) APPOINTMENTS OF INDEPENDENT NON-EXECUTIVE DIRECTORS;

(IV) INCREASE IN REGISTERED CAPITAL;

AND

(V) AMENDMENTS TO THE ARTICLES OF ASSOCIATION

The board (the “**Board**”) of directors (the “**Directors**”) of Pharmaron Beijing Co., Ltd.* (康龍化成(北京)新藥技術股份有限公司) (the “**Company**”) is pleased to announce that the Second Extraordinary General Meeting of 2022 (the “**EGM**”) of the Company was held by the Company at 6 Tai-He Road, Economic Technological Development Area, Beijing, the People’s Republic of China (the “**PRC**”) on September 23, 2022 and all the resolutions set out below were voted by way of poll.

Reference is made to the notice of the EGM (the “**Notice**”) and the circular (the “**Circular**”) of the Company, both dated September 7, 2022. Unless otherwise defined, terms used herein shall have the same meanings as those defined in the Circular.

(I) POLL RESULTS OF THE SECOND EXTRAORDINARY GENERAL MEETING OF 2022 HELD ON SEPTEMBER 23, 2022

As at the date of the EGM, the total number of issued shares of the Company (the “**Shares**”) is 1,191,067,629 Shares (comprising 990,042,879 A Shares and 201,024,750 H Shares), which was the total number of Shares entitling the Shareholders to attend and vote on all resolutions at the EGM. The total number of Shares with voting rights represented by the Shareholders attending the EGM in person or by proxy was 528,393,992 Shares, representing approximately 44.3631% of the total number of Shares.

There were no Shareholders who were required to abstain from voting in favour when casting votes on any of the resolutions at the EGM according to Rule 13.40 of the Listing Rules. There were no Shareholders who were required to abstain from voting under the Listing Rules. None of the Shareholders has stated in the Circular his/her/its intention to vote against the relevant resolutions or to abstain from voting.

Directors (including Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors, Mr. Chen Pingjin and Mr. Hu Baifeng as non-executive Directors, and Ms. Chen Guoqin, Mr. Tsang Kwan Hung Benson and Mr. Yu Jian as independent non-executive Directors) were present at the EGM.

The EGM was legally and validly convened in compliance with the requirements of the Company Law of the PRC and the Articles of Association of the Company. The Chairman of the EGM was Dr. Lou Boliang, the executive Director.

In compliance with the requirements of the Listing Rules, the Company appointed Computershare Hong Kong Investor Services Limited (the Company's H Share registrar), the supervisor of the Company, the representative from the Company's shareholders, and Zhong Lun Law Firm (the Company's PRC legal adviser) to act as the scrutineers for the vote-taking at the EGM.

The poll results in respect of the respective resolutions at the EGM were as follows:

SPECIAL RESOLUTIONS		NUMBER OF VOTES(%)		
		FOR	AGAINST	ABSTAIN
2.	Increase of registered capital.	526,867,042 (99.7110%)	1,526,950 (0.2890%)	0 (0%)
3.	Amendments to the Articles of Association.	526,866,742 (99.7110%)	1,527,250 (0.2890%)	0 (0%)
ORDINARY RESOLUTIONS		NUMBER OF VOTES(%)		
1.	By-election of independent non-executive Directors of the second session of the Board:	Resolutions below are voted by way of cumulative voting system (Number of votes) (%)		
	1.1 By-election of Ms. Li Lihua (李麗華) as an independent non-executive Director of the Company; and	468,949,621 (88.7500%)		
	1.2 By-election of Mr. Zhou Qilin (周其林) as an independent non-executive Director of the Company.	469,484,567 (88.8512%)		
		NUMBER OF VOTES(%)		
		FOR	AGAINST	ABSTAIN
4.	The Board of the Company is authorised by the general meeting to handle matters pertaining to the change of registered capital, the amendments to the Articles of Association and the procedures for filing the change of registered capital and the Articles of Association with the Market Supervision Management Department.	526,867,042 (99.7110%)	1,526,950 (0.2890%)	0 (0%)

Note:

- For the purpose of calculating the result of the resolutions, all the votes for and against shall be regarded as voting rights.

The above resolutions No. 2 and 3 were passed by the affirmative votes representing at least two-thirds of the total number of Shares held by the attending Shareholders having voting rights who attended the EGM in person or by proxy, and were duly passed as special resolutions of the Company.

Resolutions No. 1 and 4 were passed by the affirmative votes representing at least half of the total number of Shares held by the attending Shareholders having voting rights who attended the EGM in person or by proxy, and were duly passed as ordinary resolutions of the Company.

Please refer to the Circular for a full text of the resolutions.

(II) CESSATION OF OFFICE OF INDEPENDENT NON-EXECUTIVE DIRECTORS

As disclosed in the announcement of the Company dated August 29, 2022, each of Mr. Dai Lixin (“**Mr. Dai**”) and Ms. Chen Guoqin (“**Ms. Chen**”) will cease to be the independent non-executive Director of the Company and the relevant duties as committee members of the special committees of the Board (Mr. Dai will cease to be a member of the strategy committee of the Company, and Ms. Chen will also cease to be the chairwoman of the nomination committee and the remuneration and appraisal committee of the Company, and a member of the audit committee of the Company) after the conclusion of the EGM. The Board of Directors hereby extends its sincere thanks to Mr. Dai and Ms. Chen for their contributions to the Company. Mr. Dai and Ms. Chen have confirmed that there is no disagreement with the Board or the Company and there are no other matters relating to their respective cessations of office that need to be brought to the attention of the Shareholders.

(III) APPOINTMENTS OF INDEPENDENT NON-EXECUTIVE DIRECTORS

Ms. Li Lihua (“**Ms. Li**”) and Mr. Zhou Qilin (“**Mr. Zhou**”) have been appointed as independent non-executive directors of the Company at the EGM to fill in the vacancies to be left open by the planned cessations of office of Mr. Dai and Ms. Chen. Ms. Li will serve as the chairwoman of the nomination committee and the remuneration and appraisal committee of the Company, and a member of the audit committee of the Company, and Mr. Zhou will serve as a member of the strategy committee of the company. For the biographical details of Ms. Li and Mr. Zhou that are required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules, please refer to the announcement dated August 29, 2022 and the circular dated September 7, 2022. As of the date of this announcement, there has been no change in such information.

The term of office of Ms. Li and Mr. Zhou will commence from the conclusion of the EGM and will end on the expiry of the term of the current session of the Board. The Company will enter into service agreements with Ms. Li and Mr. Zhou, respectively, upon the approval of their respective appointments at the EGM. The remuneration for Ms. Li and Mr. Zhou will be RMB300,000 per annual (before tax), respectively.

The Company would like to take this opportunity to welcome Ms. Li and Mr. Zhou to join the Board.

(IV) INCREASE IN REGISTERED CAPITAL

As disclosed in the announcement of the Company dated August 29, 2022, by reason of the capitalization of reserve which formed part of the profit distribution plan of the Company for the year ended December 31, 2021, the registered capital of the Company and the total number of shares of the Company shall be changed. As a result of the change in the registered capital of the Company above, the total number of shares of the Company has increased from 794,045,086 Shares to 1,191,067,629 Shares and the registered capital of the Company has changed from RMB794,045,086 (divided into 794,045,086 Shares) to RMB1,191,067,629 (divided into 1,191,067,629 Shares).

(V) AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Reference is made to the Notice and the Circular, both dated September 7, 2022. As confirmed by the legal advisers of the Company as to the laws of the PRC, the Board has obtained the proper authorization regarding the amendments to Articles of Association as disclosed in the Notice and the Circular at the EGM. The resolution on the amendments to the Articles of Association of the Company was approved at the EGM and will take immediate effect.

By order of the Board
Pharmaron Beijing Co., Ltd.*
康龍化成(北京)新藥技術股份有限公司
Dr. Lou Boliang
Chairman

Beijing, the PRC
September 23, 2022

As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Chen Pingjin, Mr. Hu Baifeng, Mr. Li Jiaqing and Mr. Zhou Hongbin as non-executive Directors; Ms. Li Lihua, Mr. Zhou Qilin, Mr. Tsang Kwan Hung Benson and Mr. Yu Jian as independent non-executive Directors.

* *For identification purposes only*